Genenta Science (NASDAQ:GNTA) Shares Down 5.9% – Here’s What Happened

Posted by Hanz Christensen on Oct 9th, 2026

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Get Free Report)’s stock price dropped 5.9% on Thursday. The stock traded as low as $0.7101 and last traded at $0.7101. Approximately 53,588 shares were traded during trading, a decline of 17% from the average daily volume of 64,763 shares. The stock had previously closed at $0.7550.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Genenta Science from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Check Out Our Latest Research Report on Genenta Science

Genenta Science Trading Down 5.9%

The firm has a 50-day moving average of $0.99 and a 200 day moving average of $1.11.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Genenta Science stock. SmartHarvest Portfolios LLC boosted its position in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Free Report) by 656.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 134,447 shares of the company’s stock after buying an additional 116,666 shares during the quarter. SmartHarvest Portfolios LLC owned 0.57% of Genenta Science worth $90,000 at the end of the most recent quarter. 15.13% of the stock is currently owned by hedge funds and other institutional investors.

About Genenta Science

(Get Free Report)

Genenta Science S.p.A. (NASDAQ: GNTA) is a clinical-stage biotechnology company developing cell and gene therapies for cancer. The company’s approach uses a patient’s own hematopoietic stem cells, genetically modified outside the body to produce therapeutic proteins and deliver them to the tumor microenvironment.

Genenta’s lead investigational product, Temferon, is designed to generate interferon-alpha within solid tumors. The therapy is being studied primarily in glioblastoma, an aggressive form of brain cancer, with the goal of concentrating treatment in the tumor while limiting exposure to healthy tissues.